Ono Pharmaceutical Announces Establishment of Strategic Alliance Headquarters
In order to achieve its goal of serving as an R&D-oriented, international pharmaceutical company (global speciality) specializing in defined areas of research based on unique idea of "compound oriented" that is totally different from other companies in the industry, Ono has striven to discover original and innovative new drugs conforming to global standard in the company's four priority fields: prostaglandins, enzyme inhibitors, neuroscience, and intracellular signaling.
Discovery Research Alliance, newly created in April 2005, is aggressively seeking and promoting alliances with bioventure companies and research institutions within and outside Japan in order to strengthen discovery research capability by gaining access to cutting-edge technologies and discovery seeds. This newly established section has already made achievements as launching collaborative drug discovery programs relating to inhibitors of kinase, one of the intracellular enzymes that is involved in various diseases, with two U.S. bioventure companies.
Further to that, Ono has made efforts to strengthen the development pipeline by acquiring in-licensing products aggressively. This time, International Business of Development Headquarters that has been in charge of inand out-licensing activities and Discovery Research Alliance of Research Headquarters that has pursued search and alliances of discovery seeds will be integrated in a constructive way into one unit as establishing Strategic Alliance Headquarters in order to further strengthen discovery research capability and expansion of development pipeline by promoting strategic alliances. Strategic Alliance Headquarters is anticipated to take an important role in improving overall research and development capability while closely coordinating with Research Headquarters and Development Headquarters.
Most read news
Organizations
Other news from the department business & finance
Get the chemical industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.